CRISPR

CRISPR1-rps9

ID
ZDB-CRISPR-200528-2
Name
CRISPR1-rps9
Previous Names
None
Target
Sequence
5' - GCGTATTGGAGTGCTGGATG - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
la489 rps9
la490 rps9
la491 rps9
Expression
Gene expression in Wild Types + CRISPR1-rps9
No data available
Phenotype
Phenotype resulting from CRISPR1-rps9
No data available
Phenotype of all Fish created by or utilizing CRISPR1-rps9
Phenotype Fish Conditions Figures
head cdkn1a expression increased amount, abnormal rps9la490/la490 (AB) standard conditions Figure 5 with image from Chen et al., 2019
trunk hemoglobin decreased amount, abnormal rps9la490/la490 (AB) standard conditions Figure 3 with image from Chen et al., 2019
eye decreased size, abnormal rps9la490/la490 (AB) standard conditions Figure 1 with image from Chen et al., 2019
pericardium edematous, abnormal rps9la490/la490 (AB) standard conditions Figure 1 with imageFigure 5 with image from Chen et al., 2019
whole organism rps9 expression decreased amount, abnormal rps9la490/la490 (AB) standard conditions Figure 2 with image from Chen et al., 2019
trunk shortened, abnormal rps9la490/la490 (AB) standard conditions Figure 1 with imageFigure 2 with imageFigure 5 with image from Chen et al., 2019
hindbrain morphology, abnormal rps9la490/la490 (AB) standard conditions Figure 1 with image from Chen et al., 2019
pharyngeal arch cartilage absent, abnormal rps9la490/la490 (AB) standard conditions Figure 1 with image from Chen et al., 2019
whole organism mdm2 expression increased amount, abnormal rps9la490/la490 (AB) standard conditions Figure 5 with image from Chen et al., 2019
whole organism hemoglobin amount, ameliorated rps9la490/la490 (AB) chemical treatment: dexamethasone Figure 6 with image from Chen et al., 2019
head rps9 expression decreased amount, abnormal rps9la490/la490 (AB) standard conditions Figure 2 with image from Chen et al., 2019
integument melanocyte decreased amount, abnormal rps9la490/la490 (AB) standard conditions Figure 1 with image from Chen et al., 2019
hindbrain increased size, abnormal rps9la490/la490 (AB) standard conditions Figure 1 with imageFigure 2 with image from Chen et al., 2019
whole organism hemoglobin decreased amount, abnormal rps9la490/la490 (AB) standard conditions Figure 5 with imageFigure 6 with image from Chen et al., 2019
whole organism tp53 expression increased amount, abnormal rps9la490/la490 (AB) standard conditions Figure 5 with image from Chen et al., 2019
whole organism hemoglobin amount, ameliorated rps9la490/la490 (AB) chemical treatment: L-leucine Figure 6 with image from Chen et al., 2019
whole organism cdkn1a expression increased amount, abnormal rps9la490/la490 (AB) standard conditions Figure 5 with image from Chen et al., 2019
head cdkn1a expression increased amount, abnormal rps9la491/la491 (AB) standard conditions Figure 5 with image from Chen et al., 2019
trunk hemoglobin decreased amount, abnormal rps9la491/la491 (AB) standard conditions Figure 3 with image from Chen et al., 2019
eye decreased size, abnormal rps9la491/la491 (AB) standard conditions Figure 1 with image from Chen et al., 2019
pericardium edematous, abnormal rps9la491/la491 (AB) standard conditions Figure 1 with imageFigure 5 with image from Chen et al., 2019
whole organism rps9 expression decreased amount, abnormal rps9la491/la491 (AB) standard conditions Figure 2 with image from Chen et al., 2019
trunk shortened, abnormal rps9la491/la491 (AB) standard conditions Figure 1 with imageFigure 2 with imageFigure 5 with image from Chen et al., 2019
pharyngeal arch cartilage absent, abnormal rps9la491/la491 (AB) standard conditions Figure 1 with image from Chen et al., 2019
hindbrain morphology, abnormal rps9la491/la491 (AB) standard conditions Figure 1 with image from Chen et al., 2019
whole organism mdm2 expression increased amount, abnormal rps9la491/la491 (AB) standard conditions Figure 5 with image from Chen et al., 2019
whole organism hemoglobin amount, ameliorated rps9la491/la491 (AB) chemical treatment: dexamethasone Figure 6 with image from Chen et al., 2019
head rps9 expression decreased amount, abnormal rps9la491/la491 (AB) standard conditions Figure 2 with image from Chen et al., 2019
integument melanocyte decreased amount, abnormal rps9la491/la491 (AB) standard conditions Figure 1 with image from Chen et al., 2019
hindbrain increased size, abnormal rps9la491/la491 (AB) standard conditions Figure 1 with imageFigure 2 with image from Chen et al., 2019
whole organism hemoglobin decreased amount, abnormal rps9la491/la491 (AB) control Figure 5 with imageFigure 6 with image from Chen et al., 2019
whole organism tp53 expression increased amount, abnormal rps9la491/la491 (AB) standard conditions Figure 5 with image from Chen et al., 2019
whole organism hemoglobin amount, ameliorated rps9la491/la491 (AB) chemical treatment: L-leucine Figure 6 with image from Chen et al., 2019
whole organism cdkn1a expression increased amount, abnormal rps9la491/la491 (AB) standard conditions Figure 5 with image from Chen et al., 2019
nucleate erythrocyte developmental maturation delayed phase, abnormal rps9la490/la490; cz3325Tg (AB) standard conditions Figure 3 with image from Chen et al., 2019
heart nucleate erythrocyte decreased amount, abnormal rps9la490/la490; cz3325Tg (AB) standard conditions Figure 3 with image from Chen et al., 2019
trunk nucleate erythrocyte absent, abnormal rps9la490/la490; cz3325Tg (AB) standard conditions Figure 3 with image from Chen et al., 2019
nucleate erythrocyte decreased amount, abnormal rps9la490/la490; cz3325Tg (AB) standard conditions Figure 3 with image from Chen et al., 2019
nucleate erythrocyte developmental maturation delayed phase, abnormal rps9la491/la491; cz3325Tg (AB) standard conditions Figure 3 with image from Chen et al., 2019
heart nucleate erythrocyte decreased amount, abnormal rps9la491/la491; cz3325Tg (AB) standard conditions Figure 3 with image from Chen et al., 2019
trunk nucleate erythrocyte absent, abnormal rps9la491/la491; cz3325Tg (AB) standard conditions Figure 3 with image from Chen et al., 2019
nucleate erythrocyte decreased amount, abnormal rps9la491/la491; cz3325Tg (AB) standard conditions Figure 3 with image from Chen et al., 2019
trunk length, ameliorated rps9la490/la490 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
whole organism tp53 expression increased amount, abnormal rps9la490/la490 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
pericardium morphology, ameliorated rps9la490/la490 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
whole organism hemoglobin amount, ameliorated rps9la490/la490 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
whole organism cdkn1a expression increased amount, abnormal rps9la490/la490 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
whole organism mdm2 expression increased amount, abnormal rps9la490/la490 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
trunk length, ameliorated rps9la491/la491 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
whole organism tp53 expression increased amount, abnormal rps9la491/la491 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
pericardium morphology, ameliorated rps9la491/la491 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
whole organism hemoglobin amount, ameliorated rps9la491/la491 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
whole organism cdkn1a expression increased amount, abnormal rps9la491/la491 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
whole organism mdm2 expression increased amount, abnormal rps9la491/la491 + MO4-tp53 (AB) control Figure 5 with image from Chen et al., 2019
Citations